ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Busin...(nd Exchange Commission.ADVENTRX's public...)

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.

(Tables to Follow)

ADVENTRX Pharmaceuticals, Inc. and Subsidiaries

(A Development Stage Enterprise)

Summary Condensed Consolidated Financial Information

(In 000s except for per share data)

Consolidated Statement of

Operations Data:

Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007

(unaudited) (unaudited) (unaudited) (unaudited)

Revenues $- $- $500 $500

Operating expenses:

Research and development 4,741 4,422 13,073 12,047

Selling, general and

administrative 2,075 1,979 7,076 6,795

Depreciation and

amortization 40 45 131 150

Total operating expenses 6,856 6,446 20,280 18,992

Loss from operations (6,856) (6,446) (19,780) (18,492)

Interest income 79 532 644 1,731

Loss before income taxes (6,777) (5,914) (19,136) (16,761)

Provision for income

taxes - - - -

Net loss
'/>"/>